101620-71-7

Usage

Molecular structure

The compound has an isoindole-dione core with a piperidine group attached via a propyl linker, which in turn is attached to a diphenylmethoxy group.

Pharmacological significance

Potentially acting as a drug or a precursor in the synthesis of pharmaceuticals.

Further research needed

The specific biological or chemical properties of 1H-Isoindole-1,3(2H)-dione, 2-[3-[4-(diphenylmethoxy)-1-piperidinyl]propyl]- would need to be determined through additional research and testing.

Upstream product

• 5460-29-7 2-(3-bromopropyl)isoindole-1,3-dione 
• 58258-01-8 4-diphenylmethoxypiperidine 

Downstream Products

• 101620-72-8 1-(3-aminopropyl)-4-diphenylmethoxypiperidine 
• 215529-43-4 ethyl 2-[6-[3-[4-(diphenylmethoxy)piperidino]propyl-amino]imidazo[1,2-b]pyridazin-2-yl]-2-methylpropionate 
• 595598-08-6 N-[3-[4-(diphenylmethoxy)piperidino]propyl]methylamine 

Relevant academic research and scientific papers

Synthesis of eosinophil infiltration inhibitors with antihistaminic activity.

A series of [1, 2, 4]triazolo[1, 5-b]pyridazines (5) and imidazo[1, 2-b]pyridazines (6) having cyclic amines was synthesized and evaluated for antihistaminic activity and inhibitory effect on eosinophil infiltration. When a piperidine or a piperazine containing a benzhydryl group and a suitable spacer was incorporated at the 6-position, the fused pyridazines were found to exhibit both antihistaminic activity and an inhibitory effect on eosinophil chemotaxis. Above all, 6a showed potent antihistaminic activity, but little blockade of central H(1) receptors in contrast with its complete blockade of peripheral H(1) receptors as determined by an ex vivo binding assay. Furthermore, 6a inhibited eosinophil infiltration of the skin caused by a topical antigen challenge in sensitized guinea pigs, while an antihistamine terfenadine was not effective. After the pharmacokinetic study, 6a was found to be rapidly hydrolyzed to 6o, which was also orally active. Compound 6o, 2-[6-[[3-[4-(diphenylmethoxy)piperidino]propyl]amino]imidazo[1, 2-b]pyridazin-2-yl]-2-methylpropionic acid dihydrate (TAK-427), having both antihistaminic and antiinflammatory activity, is currently undergoing clinical trials as a therapeutic agent for atopic dermatitis and allergic rhinitis.